Categories AlphaGraphs, Earnings, Health Care

Bristol-Myers Q2 earnings, revenue top Street; stock dips on weak guidance

Biopharma company Bristol-Myers Squibb (NYSE: BMY) on Thursday reported higher earnings and revenues for the second quarter, The results also came in above market’s expectations. Meanwhile, the management revised down its full-year earnings guidance, sending the stock lower in the premarket session.

Revenues for the quarter rose 10% to $6.3 billion, surpassing the average analysts’ estimate of $6.11 billion. The top line was boosted by the US segment, which grew 14%. International business revenues rose 5% during the quarter.

Bristol-Myers Q2 earnings, revenue top Street; stock dips on weak guidance

The New York-based firm reported adjusted earnings of $1.18 per share, up from last year’s earnings of $1.01 per share and above Wall Street’s prediction. Net earnings attributable to shareholders climbed to f $1.4 billion or $0.87 per share from $373 million or $0.23 per share last year.

Product-wise, melanoma drug Yervoy witnessed a 17% revenue growth, while revenues of Anticoagulant Eliquis moved up 24% year-over-year.

“Through strong commercial execution and financial discipline we are establishing a solid foundation from which we can build the leading biopharma company, well-positioned to address the unmet needs of our patients and create long-term shareholder value,” said CEO Giovanni Caforio.

Melanoma drug Yervoy witnessed a 17% revenue growth, while revenues of Anticoagulant Eliquis moved up 24%

Meanwhile, the company lowered its guidance for full-year unadjusted earnings from $3.84 -$3.94 per share to $3.73- $3.83 per share. It raised the adjusted earnings guidance range from $4.10-$4.20 per share to $4.20-$4.30 per share. Research and development expenses are expected to decline in the low-double digits on an unadjusted basis, and in the mid-single digits on an adjusted basis.

Related: Bristol-Myers Squibb Q4 2018 Earnings Call Transcript

The company said it is on track to complete the acquisition of rival pharma company Celgene. Also, preparations are on for the post-acquisition integration.

Shares of Bristol-Myers dropped early Thursday after closing the previous session higher. The stock lost 18% since the beginning of the year and 24% in the last twelve months.

Listen to publicly listed companies’ earnings conference calls along with the edited closed caption text

Most Popular

Infographic: Key highlights from Best Buy (BBY) Q1 2023 earnings results

Best Buy Co., Inc. (NYSE: BBY) reported first quarter 2023 earnings results today. Enterprise revenue dropped to $10.6 billion from $11.6 billion in the year-ago period. Comparable sales were down

AutoZone (AZO) Q3 Earnings: Key financials and quarterly highlights

AutoZone, Inc. (NYSE: AZO) reported third quarter 2022 earnings results today. Net sales increased 5.9% year-over-year to $3.9 billion. Domestic same-store sales increased 2.6%. Net income decreased 0.6% to $592.6 million, while

Infographic: Zoom Video Communications (ZM) Q1 2023 earnings results

Zoom Video Communications (NASDAQ: ZM)  reported lower earnings and higher revenues for the first quarter of 2023. Earnings topped Wall Street's expectations, while revenues matched the estimates. Adjusted earnings, excluding

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top